HomeAVTX • NASDAQ
Avalo Therapeutics Inc
add
Market news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 8.76M | 80.89% |
Net income | -13.15M | 89.16% |
Net profit margin | — | — |
Earnings per share | -1.29 | — |
EBITDA | -14.53M | -179.77% |
Effective tax rate | -0.06% | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 125.05M | 13.50% |
Total assets | 138.52M | 11.96% |
Total liabilities | 15.91M | -92.92% |
Total equity | 122.62M | — |
Shares outstanding | 10.83M | — |
Price to book | 0.35 | — |
Return on assets | -25.36% | — |
Return on capital | -28.50% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -13.15M | 89.16% |
Cash from operations | -9.46M | -52.48% |
Cash from investing | — | — |
Cash from financing | — | — |
Net change in cash | -9.46M | -109.20% |
Free cash flow | -4.65M | -102.23% |
Previous close
$3.91
Day range
$3.67 - $4.03
Year range
$3.39 - $16.00
Market cap
40.60M USD
Avg Volume
67.37K
P/E ratio
0.17
Dividend yield
-
Primary exchange
NASDAQ
About
Founded
2011
Headquarters
Website
Employees
23
